| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Schedule Of Defined Benefit Plans Disclosures [Table] | ||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||
Cash flows from operating activities, continuing operations: | ||||||
Net loss | ||||||
-18,630 | -79,723 | -50,082 | - | - | - | - |
Loss on discontinued operations | ||||||
-23,255 | -66,655 | -43,365 | - | - | - | - |
Net loss | ||||||
- | - | - | -30,205 | 3,033 | - | - |
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities from continuing operations: | ||||||
Net loss | ||||||
- | - | - | - | - | -16,134 | -1,957 |
Stock-based compensation | ||||||
6,191 | 4,279 | 4,178 | 3,889 | 3,064 | 531 | 0 |
Non-cash interest expense | ||||||
5,412 | 1,287 | 912 | - | 668 | - | - |
Non-cash interest expense | ||||||
- | - | - | 1,071 | - | - | - |
Depreciation expense | ||||||
5,817 | 4,872 | 4,793 | 4,993 | 4,120 | - | 1 |
Loss on early extinguishment of debt | ||||||
- | - | -6,772 | - | - | - | - |
Amortization of intangible assets | ||||||
2,583 | 2,583 | 2,583 | 2,583 | 1,884 | - | - |
Noncash interest expense | ||||||
- | - | - | - | - | 4,272 | 868 |
Change in warrant valuation | ||||||
2,116 | 284 | 9 | -373 | -1,560 | - | - |
Change in contingent consideration valuation | ||||||
- | - | - | 9,728 | 5,246 | - | - |
Deferred income taxes | ||||||
- | -17,637 | -7,507 | - | 15,637 | - | - |
Changes in operating assets and liabilities: | ||||||
Deferred income taxes | ||||||
- | - | - | -1,423 | - | - | - |
Inventory | ||||||
4,373 | 860 | 1,093 | -237 | -1,271 | - | - |
Contract asset | ||||||
3,650 | 1,446 | - | - | - | - | - |
Prepaid expenses and other current assets | ||||||
604 | 508 | 243 | 325 | -225 | - | - |
Right-of-use asset | ||||||
-207 | - | - | - | - | - | - |
Accounts receivable | ||||||
1,523 | 3,180 | -725 | 1,831 | -3,992 | - | - |
Accounts payable, accrued expenses and other liabilities | ||||||
-364 | -858 | -352 | - | 2,152 | - | - |
Operating lease liability | ||||||
-213 | - | - | - | - | - | - |
Prepaid expenses | ||||||
- | - | - | - | - | 585 | 1 |
Other receivables | ||||||
- | - | - | - | - | 51 | -46 |
Accounts payable and accrued expenses | ||||||
- | - | - | 8,454 | - | 1,100 | 226 |
Net cash provided by operating activities, continuing operations | ||||||
16,224 | 11,022 | 19,074 | -3,202 | 8,458 | -10,866 | -816 |
Cash flows from investing activities, continuing operations: | ||||||
Acquisition of Gainesville, net of cash acquired | ||||||
- | - | - | - | 52,690 | - | - |
Purchases of property and equipment | ||||||
8,342 | 7,198 | 5,403 | 3,770 | 2,411 | - | - |
Purchases of short-term investments | ||||||
12,100 | 6,225 | 57,124 | - | - | - | - |
Proceeds from maturity of investments | ||||||
12,100 | 9,750 | 53,500 | - | - | - | - |
Net cash used in investing activities, continuing operations | ||||||
-8,342 | -3,673 | -9,027 | -3,770 | -55,101 | - | - |
Cash flows from financing activities, continuing operations: | ||||||
Proceeds from Aspire facility | ||||||
- | - | - | 7,796 | - | - | - |
Proceeds from issuance of long-term debt, net of original issue discount of $11,400 | ||||||
43,600 | 10,000 | 60,000 | - | 50,000 | - | - |
Payments on long-term debt | ||||||
- | - | 27,347 | 6,324 | 16,329 | - | - |
Fees related to early extinguishment of debt | ||||||
- | - | 4,420 | - | - | - | - |
Payment of deferred financing costs | ||||||
2,936 | 961 | 4,178 | - | 1,718 | - | - |
Proceeds from sale of common stock, net of transaction costs | ||||||
- | 16,965 | - | 50,255 | 14,812 | 30,360 | - |
Payments of withholdings on shares withheld for income taxes | ||||||
1,676 | 91 | 250 | 51 | - | - | - |
Payment of deferred equity costs | ||||||
- | - | - | - | 253 | - | 104 |
Proceeds from option exercises | ||||||
6,003 | 1,815 | 53 | - | 228 | - | - |
Proceeds from notes payable | ||||||
- | - | - | - | - | 175 | 880 |
Net cash provided by/(used in) financing activities, continuing operations | ||||||
25,991 | 27,728 | 23,858 | 51,676 | 46,740 | 30,535 | 776 |
Net increase in cash and cash equivalents from continuing operations | ||||||
33,873 | 35,077 | 33,905 | - | - | - | - |
Discontinued Operations: | ||||||
Cash flows used in operating activities | ||||||
-41,721 | -54,137 | -36,117 | - | - | - | - |
Cash flows used in investing activities | ||||||
-1,518 | -3,410 | -1,287 | - | - | - | - |
Cash flows used in financing activities | ||||||
-10,000 | - | - | - | - | - | - |
Net decrease in cash and cash equivalents from discontinued operations | ||||||
-53,239 | -57,547 | -37,404 | - | - | - | - |
Net decrease in cash and cash equivalents | ||||||
- | - | - | 44,704 | 97 | 19,669 | -40 |
Supplemental disclosure of cash flow information: | ||||||
Cash paid for interest | ||||||
14,395 | 8,134 | 5,341 | - | - | - | - |
Accretion of Series A and deemed dividend | ||||||
- | - | - | - | - | 1,270 | 440 |
Conversion of Series A and accrued dividends into common stock | ||||||
- | - | - | - | - | 7,150 | - |
Cash paid for interest | ||||||
- | - | - | 4,517 | 4,892 | - | - |
Cash paid for taxes | ||||||
- | - | 467 | - | - | - | - |
Purchase of property, plant and equipment included in accrued expenses and accounts payable | ||||||
288 | 2,301 | 235 | 808 | 208 | - | - |
Common stock issued in connection with equity facility | ||||||
301 | 357 | - | - | 285 | - | - |
Amortization of deferred equity costs | ||||||
- | 332 | - | 421 | - | - | - |
Fair value recognized for warrants | ||||||
- | 89 | 2,143 | - | - | - | - |
Baudax Bio, Inc [Member] | ||||||
Cash contribution to Baudax Bio, Inc. | ||||||
19,000 | - | - | - | - | - | - |